Taletrectinib (AB-106) has shown promising efficacy in patients with ROS1-positive non-small cell lung cancer (NSCLC), according to data from the phase 2 TRUST-II trial (NCT04919811). The global, single-arm, open-label, multicenter study evaluated taletrectinib in patients with locally advanced or metastatic ROS1-positive NSCLC, regardless of prior TKI exposure.
High Response Rates Observed
At the 2024 IASLC World Conference on Lung Cancer, investigators presented data showing a confirmed overall response rate (cORR) of 85.2% (95% CI, 72.88%-93.38%) in patients without prior exposure to a ROS1 TKI (n = 54). For patients previously treated with a ROS1 TKI (n = 47), the cORR with taletrectinib was 61.7% (95% CI, 46.38%-75.49%). The median follow-up was 15.8 months (range, 3.6-29.8) for TKI-naive patients and 15.7 months (range, 3.9-29.8) for TKI-pretreated patients.
Intracranial Activity
The TRUST-II study also demonstrated notable intracranial response rates. Among TKI-naive patients (n = 9), the intracranial response rate was 66.7% (95% CI, 29.93%-92.51%). In TKI-pretreated patients (n = 16), the intracranial response rate was 56.3% (95% CI, 29.88%-80.25%).
Tolerability
The treatment was generally well tolerated, although dose reductions were required in 37.1% of patients, with 16.4% of these reductions due to elevated liver enzymes. Jyoti Patel, MD, from Northwestern University, emphasized that taletrectinib has shown efficacy in patients with ROS1 translocations, which are notoriously difficult to treat.
